|
|
Post by mnkdfann on Sept 17, 2019 9:00:11 GMT -5
OneDrop is sold in Apple stores. Will the Bluehale device get similar coverage? It depends on how FDA labels the device. Simple medical devices, like thermometers and blood pressure monitors, can be sold anywhere while other devices can be dispensed only on the orders of a physician (i.e. the sale requires a written prescription); that implies a level of regulatory infrastructure Apple stores do not have. Since BluHale is intended to dispense a prescription drug it will probably be available through the same channels as Afrezza itself. For the sake of discussion, how hard would that be to develop? I know it is not the same thing, but Apple can manage educational orders that require verification. And Apple already has at least one certified prescribing app in its store. Perhaps Apple could not handle walk-in purchases with a prescription, but I'm open to the idea that they may have the infrastructure to be able to handle simple medical devices that are prescribed electronically in advance (through a certified e-prescribe app) without too much trouble. Having said that, I think your last line is the most likely. Besides which, why would Apple even want to bother until sale sales of Afrezza are many many multiples beyond where they are now. |
|
|
|
Post by mnkdfann on Sept 14, 2019 14:31:26 GMT -5
Being an accountant ... my next lesson is about the Federal insurance on securities. The Feds will insure your securities up to $500k per person, per account. My family consists of 3 people and I have 7 accounts in E*Trade. 3 being individual accounts and 4 joint accounts. Individual accounts are insured up to $500k ... and the joint accounts are insured up to $1M. So my family has the potential to be insured up to $5.5M for free. This may not be important to anyone and I don't lose any sleep over it. But ... if sports or bocagirl hack into my account and steal shares ... the Feds will reimburse me. (Not using real names to protect the innocent) Get the picture? Not worried? If you have 5k shares and the pps goes to $100 ... you are at max for insured shares.  And yes, I will be in uninsured territory long before we hit $100 pps. Heck, it's only money. For more information ... send $20 to www.mytakeonit.com for my news letter. But, that's mytakeonit Mtot, Your website is down. Tried with chrome, ie, safari, Firefox and bluhale Count your blessings: mnkd.proboards.com/post/184689 |
|
|
|
Post by mnkdfann on Sept 12, 2019 18:58:21 GMT -5
Well, I sold my (very small number of) remaining shares yesterday (at a profit). I'll buy back if it dips back down in the weeks ahead.
Of course, with my investing luck, there will be a UTHR buyout of MNKD announced tomorrow.
|
|
|
|
Post by mnkdfann on Sept 11, 2019 12:30:30 GMT -5
I would suggest creating a four question poll to yield maximum insight into public opinion. - Is HfM along with Bill actually helping Mannkind?
- Is HfM along with Michael Kovacocy actually helping Mannkind?
- Is HfM along with Bill actually hurting Mannkind?
- Is HfM along with Michael Kovacocy actually hurting Mannkind?
Did Bill invite MK into the HFM fold, and is MK is one of Bill's significant advisors? IDK for sure. I had thought so, based on what I've seen / read. If so, it becomes harder to separate Bill and MK in my mind. |
|
|
|
Post by mnkdfann on Sept 11, 2019 0:02:42 GMT -5
|
|
|
|
Post by mnkdfann on Sept 9, 2019 7:44:41 GMT -5
From a 2014/5 report of the Managing Board of Bioton:
"On 01.12.2014 the Company and BIOMM S.A. with the seat in Brazil ("Biomm") concluded an agreement on granting Biomm and/or its subsidiaries the exclusive right to commercialize recombinant human insulins produced by the Company ("Products") in the territory of Brazil ("Agreement"). The Agreement has been concluded for 15 years. The commencement of Products supplies is made conditional upon the Products' registration in the territory of Brazil."
At first glance, seems it took a long time for the deal with Bioton to go nowhere.
|
|
|
|
Post by mnkdfann on Sept 7, 2019 20:12:42 GMT -5
Kite, isn’t there another conference also later in the month? I have on my calendar that MNKD is presenting at the Rodman & Renshaw 21st Annual Global Healthcare Conference, which is happening from Sunday, September 8 until Tuesday, September 10 in NYC. I've had it on my calendar for some time now but can't find the source I got it from... I guess we will find out in the next few days I think you mixed two conferences into one: 2019 Global Investment Conference by Rodman and Renshaw and sponsored by HC Wainwright and the 2019 Morgan Stanley 17th Annual Global Healthcare Conference. Both are in NYC this week, on (at least partially) overlapping days. AFAIK, Mannkind is only presenting at the first. |
|
|
|
Post by mnkdfann on Sept 7, 2019 10:18:35 GMT -5
|
|
|
|
Post by mnkdfann on Sept 5, 2019 17:26:13 GMT -5
|
|
|
|
Post by mnkdfann on Sept 5, 2019 8:32:46 GMT -5
Mnkdfan Long Term Capital. Read about it. Not at all sure what point you are making. In any case, I'm already well familiar with LTCM. Its strategy of betting on outliers went bust, and even while successful it never had annual returns as good as what some above are expecting for Mannkind over the next year. It took LTCM approx. 4 years to turn 1180 into 4000 yet people expect MNKD to go from 1.18 to 4 in a little over a year? As I said near the start of my posts on this topic, it COULD happen. But personally I would not expect it to happen that quickly.  |
|
|
|
Post by mnkdfann on Sept 4, 2019 20:40:20 GMT -5
It is true that the share price does not have to hit $4 for someone to sell the options early and make a profit, just so long as the share price is moving up faster than the time decay is destroying the option price, However, it is unlikely that the Mannkind SP will hit $4 by the 2021 expiry date (if that is what you were talking about). Of course, it COULD happen, but if it did then that would likely make MNKD one of the top 10 best performing stocks of 2020. To go from $1.18 to $4 in about 16 months would be a phenomenal rate of return. That sort of return would beat the performance of every one of the stocks on this list of the best performers of 2018, for instance: ca.finance.yahoo.com/news/14-best-performing-stocks-2018-100000910.htmlAn incomplete list to say the least, extremely misleading it doesn’t include the price fluctuations between those dates. Tandem (tndm) price Jan 2. $2.52 price on Nov. 9 $37.19 Where do they rank on your list if best performers ? It was not 'my' list, but whatever. Yes, you are correct, the sort of return I was describing (from $1.18 to $4 in about 16 months) is so run of the mill and ordinary that it barely warrants comment. So I was mistaken. Betting everything on seeing $4 by January 2021 is a good investment. Go for it.  |
|
|
|
Post by mnkdfann on Sept 4, 2019 19:32:29 GMT -5
What makes you think the 2021 $4s would be a loss? It is true that the share price does not have to hit $4 for someone to sell the options early and make a profit, just so long as the share price is moving up faster than the time decay is destroying the option price, However, it is unlikely that the Mannkind SP will hit $4 by the 2021 expiry date (if that is what you were talking about). Of course, it COULD happen, but if it did then that would likely make MNKD one of the top 10 best performing stocks of 2020. To go from $1.18 to $4 in about 16 months would be a phenomenal rate of return. That sort of return would beat the performance of every one of the stocks on this list of the best performers of 2018, for instance: ca.finance.yahoo.com/news/14-best-performing-stocks-2018-100000910.html |
|
|
|
Post by mnkdfann on Sept 4, 2019 9:20:38 GMT -5
There seem to be two main meanings. I've no idea which meaning is more popular / common. Hope this isn't a case where some English speaker picked the wrong word to use in a foreign market.
Portuguese-English
alterar
[awteˈrar]
transitive verb
1. (mudar) to alter
2. (falsificar) to falsify
alterar-se reflexive verb
1 (mudar-se) to change
2 (enfurecer-se) to lose one's temper
|
|
|
|
Post by mnkdfann on Sept 3, 2019 16:39:02 GMT -5
Models calibrated to past performance ALWAYS turn out well. They certainly haven't for MNKD. We remember the share price leading up to AdCom and then approval. Based on that past performance, we had reason to expect great things going forward. Past performance sure wasn't indicative in that example. Poe's Law strikes again? |
|
|
|
Post by mnkdfann on Aug 30, 2019 8:53:19 GMT -5
|
|
And yes, I will be in uninsured territory long before we hit $100 pps. 
